A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy

被引:198
作者
Betts, T
Waegemans, T
Crawford, P
机构
[1] Univ Birmingham, Seizure Clin, Birmingham, W Midlands, England
[2] UCB Pharma, Brussels, Belgium
[3] York Dist Hosp, York, N Yorkshire, England
来源
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY | 2000年 / 9卷 / 02期
关键词
antiepileptic drugs; seizures; refractory epilepsy; levetiracetam; add-on therapy; titration;
D O I
10.1053/seiz.2000.0380
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The aim of this study was to determine the tolerability and efficacy of two oral regimens of levetiracetam, 1000 mg and 2000 mg twice daily, as add-on treatment without titration in patients with refractory epilepsy. After a 1- to 4-week baseline, 119 patients were randomized to receive levetiracetam 2000 mg daily, 4000 mg daily, or placebo for a 24-week double-blind period, then levetiracetam 4000 mg daily in a 24-week open-label phase. Somnolence was the most common reason for discontinuation, and along with asthenia, occurred more frequently with levetiracetam than placebo. Responder rates were higher with levetiracetam 2000 mg and 4000 mg daily (48.1% [P < 0.05] and 28.6% [NS], respectively) than placebo (16.1%). In the open-label phase, the overall responder rate was 43.0%. Switching from placebo to levetiracetam increased the overall responder rate from 16.7% to 44.0%. No such increase was observed with patients initiated on levetiracetam 2000 mg daily. Levetiracetam initiated at doses of 2000 mg or 4000 mg daily without titration is well-tolerated and effective as add-on therapy in patients with partial and/or generalized seizures. The higher dose may be related to an increased incidence of somnolence and is not necessarily more effective than the lower dose. (C) 2000 BEA Trading Ltd.
引用
收藏
页码:80 / 87
页数:8
相关论文
共 13 条
  • [1] [Anonymous], TOLERANCE BENEFICIAL
  • [2] PROPOSAL FOR REVISED CLINICAL AND ELECTROENCEPHALOGRAPHIC CLASSIFICATION OF EPILEPTIC SEIZURES
    BANCAUD, J
    HENRIKSEN, O
    RUBIODONNADIEU, F
    SEINO, M
    DREIFUSS, FE
    PENRY, JK
    [J]. EPILEPSIA, 1981, 22 (04) : 489 - 501
  • [3] Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy
    Gower, AJ
    Hirsch, E
    Boehrer, A
    Noyer, M
    Marescaux, C
    [J]. EPILEPSY RESEARCH, 1995, 22 (03) : 207 - 213
  • [4] Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy
    Klitgaard, H
    Matagne, A
    Gobert, J
    Wülfert, E
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 353 (2-3) : 191 - 206
  • [5] Löscher W, 1998, J PHARMACOL EXP THER, V284, P474
  • [6] PROFILE OF UCB-L059, A NOVEL ANTICONVULSANT DRUG, IN MODELS OF PARTIAL AND GENERALIZED EPILEPSY IN MICE AND RATS
    LOSCHER, W
    HONACK, D
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 232 (2-3) : 147 - 158
  • [7] Loscher W, 1993, CURR OPIN INVEST DR, V2, P1067
  • [8] COMPARISON OF CARBAMAZEPINE, PHENOBARBITAL, PHENYTOIN, AND PRIMIDONE IN PARTIAL AND SECONDARILY GENERALIZED TONIC CLONIC SEIZURES
    MATTSON, RH
    CRAMER, JA
    COLLINS, JF
    SMITH, DB
    DELGADOESCUETA, AV
    BROWNE, TR
    WILLIAMSON, PD
    TREIMAN, DM
    MCNAMARA, JO
    MCCUTCHEN, CB
    HOMAN, RW
    CRILL, WE
    LUBOZYNSKI, MF
    ROSENTHAL, NP
    MAYERSDORF, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (03) : 145 - 151
  • [9] THE NOVEL ANTIEPILEPTIC DRUG LEVETIRACETAM (UCB L059) APPEARS TO ACT VIA A SPECIFIC BINDING-SITE IN CNS MEMBRANES
    NOYER, M
    GILLARD, M
    MATAGNE, A
    HENICHART, JP
    WULFERT, E
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 286 (02) : 137 - 146
  • [10] The clinical pharmacokinetics of the newer antiepileptic drugs - Focus on topiramate, zonisamide and tiagabine
    Perucca, E
    Bialer, M
    [J]. CLINICAL PHARMACOKINETICS, 1996, 31 (01) : 29 - 46